1. Scrip
  2. >>Therapy Areas
  3. >>Sensory

Astellas’ Izervay Joins Geographic Atrophy Market, Intensifying Competition

 
• By Jessica Merrill

The C5 inhibitor, recently acquired by Astellas, will be commercially available in two to four weeks and will compete against Apellis Pharma’s Syfovre.

competitive edge
Astellas hopes to have a competitive edge over Apellis in geographic atrophy • Source: Shutterstock

Astellas Pharma, Inc.’s Izervay (avacincaptad pegol intravitreal solution) is the second drug approved in the US for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in six months, following the US Food and Drug Administration’s approval of Apellis Pharmaceuticals, Inc.’s Syfovre (pegcetacoplan injection) in February, and will test the early commercial traction that Apellis has reached.

Key Takeaways
  • Astella’s Pharma’s Izervay is the second drug newly approved for geographic atrophy.
  • Izervay will compete against Apellis’ Pharmaceuticals’ Syfovre, which launched in February.
  • The approval of Izervay follows Astella’s acquisition of Iveric Bio in July

The two drugs are the first approved for geographic atrophy and are competing for share in the potentially multi-billion-dollar market

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

More from Therapy Areas

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.